Jinwu Financial News | According to the Zhongtai Securities Report, in 2023, Novartis Health (06606) Chang Weiqing series products are expected to achieve operating revenue of 1,193 billion yuan, an increase of 235% over the previous year, and is expected to achieve confirmed revenue of 1.040,800 copies, an increase of 188% over the previous year. At present, the company's sales, marketing, operation and R&D management systems in the colorectal cancer early screening market have all entered steady development, which is sufficient to effectively support vertical and horizontal commercial expansion. At the same time, Chang Weiqing's entry and volume in public hospitals have accelerated markedly, laying the foundation for Chang Weiqing's market penetration target of 5% in 2025.
At the end of 2023, the balance of the company's accounts receivable was about 1,468 million yuan, of which more than 70% came from revenue in the past 6 months, and accounts receivable that were less than 90 days old was about 452 million yuan, accounting for about 31% of the company's accounts receivable. The company continued to strengthen accounts receivable management, and the return of capital was significantly accelerated during the reporting period. It is expected that the repayment amount will continue to increase rapidly in 2024, promoting continuous optimization of the quality of the company's statements and achieving healthy and sustainable growth.
According to the bank, the company considered to be a leading domestic cancer screening listed company. It has large market space, a good competitive pattern, fast performance growth, good scarcity, and maintains a “buy” rating.